NASDAQ$ALKS
Alkermes plc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter of 2024, marking the first full quarter as a profitable, pure-play neuroscience company.
Alkermes reported a solid first quarter in 2024 with total revenues of $350.4 million and GAAP net income from continuing operations of $38.9 million. The company is advancing its strategic priorities, including LYBALVI's prescription growth and ALKS 2680's development.
- Total revenues for the first quarter of 2024 were $350.4 million.
- GAAP net income from continuing operations was $38.9 million, with diluted GAAP earnings per share from continuing operations at $0.23.
- LYBALVI revenues grew 50% compared to the first quarter of 2023.
- Alkermes is advancing ALKS 2680, a novel, investigational, oral orexin 2 receptor (OX2R) agonist, with phase 2 studies planned.
Headline financials
Revenue & EPS history
Alkermes · Revenue · Quarterly
$350M
Revenue by segment
Alkermes · $232M total across 3 segments · Q3 2023
- VIVITROL$99.3M+2.9%42.8%
- ARISTADA$81.8M+8.1%35.3%
- LYBALVI$50.7M+87.1%21.9%
Forward guidance
Alkermes reiterates its financial expectations for 2024, as set forth in its press release dated Feb. 15, 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.6%
Avg return
Earnings day
-0.0%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
27 / 60 earnings
Positive
+16.6%
Q4 2017
Best reaction
-14.8%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.2% | +2.5% | +27.0% | |
| Q4 2025 | -6.6% | -9.4% | -12.0% | |
| Q3 2025 | +3.9% | +3.3% | +0.0% | |
| Q1 2025 | +6.3% | +5.5% | +6.4% | |
| Q4 2024 | +4.8% | +12.3% | +6.5% | |
| Q3 2024 | -6.3% | -5.1% | +3.3% | |
| Q2 2024 | +12.2% | +11.7% | +11.8% | |
| Q1 2024 | -2.8% | -1.8% | -4.6% | |
| Q4 2023 | +15.0% | +8.6% | +2.7% | |
| Q3 2023 | -2.4% | -4.0% | -3.7% | |
| Q2 2023 | -1.8% | -5.1% | -11.9% | |
| Q1 2023 | -7.1% | -6.1% | -3.9% | |
| Q4 2022 | +4.0% | +2.9% | -3.6% | |
| Q3 2022 | +3.8% | +0.3% | +12.2% | |
| Q2 2022 | -9.7% | -14.4% | -16.5% | |
| Q1 2022 | +9.8% | +6.4% | +12.5% | |
| Q4 2021 | +8.8% | +7.6% | +12.1% | |
| Q3 2021 | -8.2% | -5.0% | -28.7% | |
| Q2 2021 | +5.9% | +11.6% | +28.9% | |
| Q1 2021 | -3.2% | -1.6% | +0.8% | |
| Q4 2020 | -11.8% | -13.7% | -15.3% | |
| Q3 2020 | +5.6% | +5.9% | +20.2% | |
| Q2 2020 | -8.8% | -7.4% | -19.0% | |
| Q1 2020 | -14.8% | -14.7% | +1.6% | |
| Q4 2019 | -7.0% | -7.8% | -15.5% | |
| Q3 2019 | +5.7% | +6.0% | +13.9% | |
| Q2 2019 | -10.2% | +1.2% | -12.3% | |
| Q1 2019 | -12.2% | -12.7% | -31.1% | |
| Q4 2018 | -1.2% | +3.6% | +3.3% | |
| Q3 2018 | +3.0% | +6.5% | -11.6% | |
| Q2 2018 | -0.1% | -0.3% | +2.0% | |
| Q1 2018 | +1.5% | +1.4% | +3.9% | |
| Q4 2017 | +16.6% | +23.0% | +12.0% | |
| Q3 2017 | +0.7% | -1.5% | +3.2% | |
| Q2 2017 | -4.1% | -5.4% | -12.4% | |
| Q1 2017 | +2.0% | +2.4% | +1.0% | |
| Q4 2016 | -2.9% | -4.6% | +3.7% | |
| Q3 2016 | -1.4% | +4.0% | +8.4% | |
| Q2 2016 | -3.6% | -6.0% | -14.1% | |
| Q1 2016 | -2.0% | — | — | |
| Q4 2015 | -1.4% | — | — | |
| Q3 2015 | +7.6% | — | — | |
| Q2 2015 | +2.4% | — | — | |
| Q1 2015 | +3.1% | — | — | |
| Q4 2014 | -3.4% | — | — | |
| Q3 2014 | +7.7% | — | — | |
| Q2 2014 | -7.2% | — | — | |
| Q1 2014 | +3.2% | — | — | |
| Q4 2013 | -7.7% | — | — | |
| Q3 2013 | -3.7% | — | — | |
| Q2 2013 | +3.5% | — | — | |
| Q1 2013 | +3.9% | — | — | |
| Q4 2010 | -1.0% | — | — | |
| Q4 2012 | -9.9% | — | — | |
| Q3 2012 | +2.2% | — | — | |
| Q3 2011 | +2.2% | — | — | |
| Q2 2011 | -7.7% | — | — | |
| Q2 2012 | -7.7% | — | — | |
| Q4 2011 | -7.7% | — | — | |
| Q2 2010 | -3.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro